Feed XERS
XE

Xeris Biopharma Holdings, Inc. XERS · NASDAQ

$10.31 +2.38% (+$0.24)

Market cap
$1.74B
Enterprise value
$1.91B
P/E
-
Forward P/E
1,925.3x
PEG
-
P/S
5.2x
P/FCF
31.4x
EV/EBITDA
116.1x
ROIC
12.5%
Gross margin
83.3%
Net margin
-5.1%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
10.2x
Beta
0.84
Free float
94.9%

About the company

Xeris Biopharma Holdings, Inc. (XERS) is a biotechnology company focused on developing innovative therapeutic treatments for patients with metabolic disorders and endocrine diseases. Their main focus is on developing fixed-dose formulations of therapeutic drugs that can improve patients' quality of life and simplify their treatment regimen. Xeris Biopharma concentrates on areas such as diabetic hypoglycemia, type 1 and 2 diabetes, and adrenal insufficiency. The company is known for its innovative technologies in drug formulation and applications for patients with chronic conditions. Shares of Xeris Biopharma Holdings, Inc. (XERS) may be suitable for investors seeking opportunities in the biotechnology sector with potential for innovative treatments and growth prospects.

Sector

Healthcare

Industry

Biotechnology

CEO

John Shannon

Employees

435

Headquarters

Chicago

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.